BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
288 results:

  • 1. Systematic analysis of mucosal-associated invariant T cells in haematological malignancies.
    Bacova B; Cierny J; Nemcekova L; Smetanova/Brozova J; Novak J
    Scand J Immunol; 2024 Jun; 99(6):e13364. PubMed ID: 38720521
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. High Level of CD8
    Kwaśnik P; Zaleska J; Link-Lenczowska D; Zawada M; Wysogląd H; Ochrem B; Bober G; Wasilewska E; Hus I; Szarejko M; Prejzner W; Grzybowska-Izydorczyk O; Klonowska-Szymczyk A; Mędraś E; Kiełbus M; Sacha T; Giannopoulos K
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667336
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Unlocking the potential: A novel prognostic index signature for acute myeloid leukemia.
    Zhang LQ; Liang YC; Wang JX; Zhang J; La T; Li QZ
    Comput Biol Med; 2024 May; 173():108396. PubMed ID: 38574529
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.
    Han L; Xing H; Cao W; Song Y; Jiang Z; Yu J
    Expert Opin Biol Ther; 2024 Apr; 24(4):221-223. PubMed ID: 38506624
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade.
    Mukherjee N; Katsnelson E; Brunetti TM; Michel K; Couts KL; Lambert KA; Robinson WA; McCarter MD; Norris DA; Tobin RP; Shellman YG
    Cell Death Dis; 2024 Mar; 15(3):198. PubMed ID: 38459020
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
    Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Genomic features reveal potential benefit of adding anti-pd-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
    Chen Z; Huang H; Huang H; Yu L; Weng H; Xiao J; Zou L; Zhang H; Liang C; Zhou H; Guo H; Wang Z; Li Z; Wu T; Zhang H; Wu H; Peng Z; Zhai L; Chen X; Liang Y; Hong H; Lin T
    Leukemia; 2024 Apr; 38(4):829-839. PubMed ID: 38378844
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia.
    Huang T; Leung B; Huang Y; Price L; Gui J; Lau BW
    PLoS One; 2024; 19(1):e0292375. PubMed ID: 38289944
    [TBL] [Abstract] [Full Text] [Related]  

  • 9.
    Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. CD8 + T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia.
    Zhong F; Yao F; Jiang J; Yu X; Liu J; Huang B; Wang X
    Inflamm Res; 2024 Mar; 73(3):329-344. PubMed ID: 38195768
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Clinicopathological Study of pd-1/PD-L1 Expression in Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.
    Masoud R; Eladl AE; El-Ashwah S; Abbas A; Kandil W
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4243-4252. PubMed ID: 38156860
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Spatially Resolved Tumor Microenvironment Predicts treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
    Aoki T; Jiang A; Xu A; Yin Y; Gamboa A; Milne K; Takata K; Miyata-Takata T; Chung S; Rai S; Wu S; Warren M; Strong C; Goodyear T; Morris K; Chong LC; Hav M; Colombo AR; Telenius A; Boyle M; Ben-Neriah S; Power M; Gerrie AS; Weng AP; Karsan A; Roth A; Farinha P; Scott DW; Savage KJ; Nelson BH; Merchant A; Steidl C
    J Clin Oncol; 2024 Mar; 42(9):1077-1087. PubMed ID: 38113419
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. pd-1/PD-L1 Interaction Regulates BCL2, KI67, BAX, and CASP3, Altering Proliferation, Survival, and Apoptosis in Acute Myeloid leukemia.
    Soltani M; Vosoughi M; Ganjalikhani-Hakemi M; Shapoorian H; Beshkar P; Eskandari N; Ghezelbash B
    Iran J Allergy Asthma Immunol; 2023 Oct; 22(5):495-503. PubMed ID: 38085150
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Development of pd-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia.
    Wang Q; Huang H; Liang P; Wang L; Zheng J; Zhang Y; Wang H
    Med Oncol; 2023 Dec; 41(1):14. PubMed ID: 38078948
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
    Al-Sawaf O; Ligtvoet R; Robrecht S; Stumpf J; Fink AM; Tausch E; Schneider C; Boettcher S; Mikusko M; Ritgen M; Schetelig J; von Tresckow J; Vehling-Kaiser U; Gaska T; Wendtner CM; Chapuy B; Fischer K; Kreuzer KA; Stilgenbauer S; Staber P; Niemann C; Hallek M; Eichhorst B
    Nat Med; 2024 Jan; 30(1):240-248. PubMed ID: 38071379
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Identification and validation of necroptosis-related gene signatures to predict clinical outcomes and therapeutic responses in acute myeloid leukemia.
    Wen XM; Xu ZJ; Ma JC; Xia PH; Jin Y; Chen XY; Qian W; Lin J; Qian J
    Aging (Albany NY); 2023 Nov; 15(24):14677-14702. PubMed ID: 37993258
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
    de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
    Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Immune characteristics and prognostic implications of mucosal-associated invariant T cells in acute myeloid leukemia.
    Peng Q; Huang R; Wang H; Xiao H; Wang Y; Zhai Z; Wang Z
    Cancer Immunol Immunother; 2023 Dec; 72(12):4399-4414. PubMed ID: 37932426
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Identification of cellular senescence-related signature for predicting prognosis and therapeutic response of acute myeloid leukemia.
    Zhong F; Yang Y; Yao F; Liu J; Yu X; Wang XL; Huang B; Wang XZ
    Aging (Albany NY); 2023 Oct; 15(20):11217-11226. PubMed ID: 37845004
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 15.